Genmab — Juli 2018
-
Igen fra Twitter. Jeg ved ikke om det er nyt, men ser interesant ud https://twitter.com/fezziwig2008/status/1019661134847201281?s=21
-
New trial - Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma - https://clinicaltrials.gov/ct2/show/NCT03590652?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=07%2F17%2F2018&rank=1
-
God morgen
-
God morgen.
-
-
-
act, her udtager man også t-celler og fremstiller i laboratoriet en hybridform af to t-celle-undertyper - Th1 og Th17 - som kombinerer de cancerbekæmpende egnskaber ved Th1-cellerne med evnen hos Th17 til at forny sig selv og regenermere, og som sammen med et cd-38 antistof kan angribe tumorer mere effektivt.
-
Immatics, som Genmab netop har indledt samarbejde med, har en del på bedding inden for ACT i samarbejde med MD Anderson. https://immatics.com/act.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind